EUCTR2004-001020-20-DE进行中（未招募）不适用
A Phase II multicenter, randomized, double-blind, placebo-controlled, dose ranging, parallel group study of the safety and efficacy of the oral Neurokinin-1 Receptor Antagonist, GW679769, when administered as 50 mg, 100 mg, and 150 mg oral tablets in combination with Ondansetron Hydrochloride and Dexamethasone for the rrevention of chemotherapy-induced nausea and vomiting in cancer subjects receiving moderately emetogenic chemotherapy.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 708
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male, or female not of childbearing potential (i.e., physically incapable of becoming pregnant, including postmenopausal females and those who have had attained such status via surgical means) or premenopausal women who demonstrate a negative serum or a negative urine pregnancy test within 24 hours prior to the first administration of any study medication or GW679769 investigational product and agrees to:
- •a) abstain from sexual intercourse for two (2) weeks prior to administration of the first dose of study medication or GW679769 investigational product until 30 days after the final dose of study medication or GW679769 investigational product, or
- •b) use hormonal methods of birth control (e.g., oral, injectable, or implantable) or other highly effective method of contraception [e.g., an intrauterine device (IUD)] in conjunction with a barrier method of contraception (condom, spermicidal foam, sponge, gel, diaphragm) if engaging in sexual intercourse for at least seven (7) days prior to the first dose of study medication or GW679769 investigational product and continuing until 30 days after the final dose of study medication or GW679769 investigational product.
- •2. At least 18 years of age.
- •3. Diagnosed with a malignant solid tumor, and is scheduled to receive their first course of chemotherapy as outlined below and in Section (Chemotherapeutic Regimens).
- •a) Chemotherapeutic regimens must not contain any therapeutic agents that are considered highly emetogenic as defined within this protocol [ see Section Appendix 3: Emetogenic Risk of Chemotherapy (Generic Names)”].
- •b) All chemotherapeutic agents will be administered according to individual institutional standards, including measures to ensure adequate hydration of the subject.
- •4. Karnofsky Performance Scale score of at least 70.
- •5. Hematologic and metabolic status must be adequate for receiving the moderately emetogenic chemotherapy regimen previously described and meet the following criteria:
- •White blood cells (WBC) > 3000/mm3
- •Platelets > 100,000/mm3
- •Absolute neutrophil count (ANC) > 1500/mm3
- •Serum creatinine < 1.5 mg/dL
- •Liver enzymes must be below the following limits:
- •Without known liver metastases: Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 2.5 X the upper limit of normal.
- •With known liver metastases: AST and/or ALT < 5.0 X the upper limit of normal.
- •6. Subject should be able and willing to complete daily components of the subject diary on study Day 1 and until the end of the 120 hour follow-up assessment period (beginning at the initiation of chemotherapy on study Day 1). In addition subjects should be available to respond to daily follow-up contacts by study personnel and complete a study Day 6 - 10 Visit.
- •7. Subject should understand the nature and purpose of this study and the study procedures and have signed an informed consent form for this study to indicate this understanding.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Has previously received cytotoxic chemotherapy. A history of previous biological or hormonal therapy will be permitted.
- •2. Is scheduled to receive highly emetogenic chemotherapeutic agents as defined by this protocol
- •3. Is scheduled to receive adjuvant chemotherapy with cyclophosphamide-containing regimens, neo-adjuvant cyclophosphamide-containing regimens will not be excluded.
- •4. A female subject who is pregnant or lactating.
- •5. An unwillingness of the male subject to use a condom with spermicide in addition to having their female partner use another form of contraception such as an IUD, diaphragm with spermicide, oral contraceptives, injectable progesterone, subdermal implants, or a tubal ligation if the woman could become pregnant from the time of the first dose GW679769 investigational product until 84 days following administration of the final dose GW679769 investigational product.
- •6. Has received radiation therapy to the abdomen or the pelvis in the seven (7) days prior to receiving the first dose of study medication or GW679769 investigational product and/or will receive radiation therapy to the abdomen or the pelvis in the six (6) days following the first dose of study medication or GW679769 investigational product.
- •7. The subject has experienced emesis (i.e., vomiting and/or retching) or clinically significant nausea in the 24 hours prior to receiving their first dose of any study medication or GW679769 investigational product.
- •8. Has a known central nervous system primary or metastatic malignancy, unless successfully treated with excision or radiation and has been medically stable for at least 1 week prior to receiving the first dose of study medication or GW679769
- •9. Has an etiology for emesis and nausea including, but not limited to, gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, and/or active peptic ulcer.
- •10. Has any known history of peptic ulcer disease and who, in the investigator’s opinion, may be at risk for ulcer perforation or bleeding
- •11. Has an active systemic infection or any uncontrolled disease (other than malignancy) which, in the opinion of the Investigator, may confound the results of the study or pose an unwarranted risk to the subject. Subjects with a previous, but not current, history of alcoholism may be permitted provided that, in the Investigator's opinion, the subject's disease state will not confound the results of the study.
- •12. Has initiated systemic corticosteroid therapy at any dose within 72 hours prior to receiving the first dose of study medication or GW679769 investigational product except where indicated as prophylactic medication for taxane therapy [(e.g., paclitaxel or docetaxel) see Section 4 Study Design]. However, topical steroids and inhaled corticosteroids with a steroid dose of < 10 mg prednisone daily or its equivalent are permitted.
- •13. Is scheduled to receive bone marrow transplantation and/or stem cell rescue with this course of chemotherapy.
- •14. Has a known hypersensitivity or contraindication to ondansetron hydrochloride or ondansetron, another 5-HT3 receptor antagonist, dexamethasone, or any component of GW679769 or GW679769B.
- •15. Has previously received an NK-1 receptor antagonist, with the exception of GW679769 previously administered in prior study cycles for those subjects continuing study participation beyond Cycle 1.
- •16. Has received an investigational drug in the previous 30 days or who is scheduled to receive any investigational dr
研究者
相似试验
进行中（未招募）
不适用
A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn’s disease (Ileo-Colitis)ACTIVE CROHN'S DISEASEMedDRA version: 14.1Level: LLTClassification code 10021315Term: Ileitis terminalSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2011-002640-27-ITGIULIANI
进行中（未招募）
1 期
A Study to Investigate the Efficacy, Safety and Tolerability of RO7017773 in Participants Aged 15 to 45 Years with Autism Spectrum Disorder (ASD)EUCTR2019-003524-20-ITF. HOFFMANN - LA ROCHE LTD.105
进行中（未招募）
不适用
A phase II multicenter, randomized, double-blind, controlled vs placebo, dose-finding study on the efficacy and safety of GED-0301, in patients with active Crohn’s disease (Ileo-Colitis)EUCTR2011-002640-27-DEGIULIANI160
进行中（未招募）
不适用
A phase II multi-center, randomized, double-blind, controlled vs placebo, long-term extension study to evaluate the safety and tolerability of 40 mg GED-0301for the maintainance of Crohn’s disease in remission.EUCTR2011-005678-47-ITGIULIANI
进行中（未招募）
1 期
A study to evaluate the efficacy and safety of T 817MA in patients with mild cognitive impairment due to Alzheimer’s Disease or mild Alzheimer’s Disease.Patients to be randomly allocated to either placebo or investigational drug; assignment will be unknown to patients and doctor.Mild cognitive impairment due to Alzheimer's Disease or mild Alzheimer's Disease.MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852MedDRA version: 21.1Level: LLTClassification code 10009846Term: Cognitive impairmentSystem Organ Class: 100000004852EUCTR2018-003567-66-GBFUJIFILM Toyama Chemical Co., Ltd.200